[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diagnostic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diagnostic":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,39,63,87,118,150],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100645134","deepview-hhf-training-and-validation-study-100645134",false,"NCT07677657","Deepview HHF Training and Validation Study","Deepview HHF Training and Validation Label Expansion Study","UK HHF","Inclusion Criteria:\n\n1. Willing and able to give informed consent, have a witnessed verbal consent, family discussion if intubated and retrospective consent for those that are intubated\n2. Life expectancy \\> 1 month\n3. Thermal burn mechanism (flame, scald, or contact)\n4. The Study Burn(s) occurred less than 72 hours prior to the time of first imaging\n5. Minimum burn wound size for adult or paediatric participants is 0.25% TBSA per region\n6. Have burn(s) on the head, hands and\u002For feet that meet the criteria for a Study Burn. If multiple regions meet the Study Burn criteria, per the discretion of the Investigator, all Study Burn regions should be included.\n\nExclusion Criteria:\n\n1. Sepsis at the time of enrolment\n2. Infection of the burn wound at the time of enrolment\n3. Immunosuppression \u002F radiation \u002F chemotherapy \\\u003C 3 months prior to enrolment\n4. Concurrent use of investigational products with a known effect on the burn sites; and\u002For imaging\n5. Concurrent use of products such as chemical debriding agents, skin substitutes and others that the principal investigator deems will have an impact on the image quality and healing potential of a Study Burn\n6. Any condition that, in the opinion of the Investigator, may prevent compliance with the study requirements or compromise Participant safety\n7. Participants without a burn on the hands, feet, head or neck, or burns located on these regions only on the palmar or plantar surfaces\n8. Chemical or any other non-thermal burns\n\n8\\. Participants anticipated to or undergoing enzymatic debridemen9","ALL",{"count":19,"type":20},280,"ESTIMATED","OBSERVATIONAL","The purpose of this Study is to help expand the use of the DeepView AI System so that it can assess burn injuries on the hands, head\u002Fface, and feet. To do this, the Study will collect new images of burns in these areas. Some of these images will be used to improve and retrain the AI system, while others will be used to test how well the updated system performs. The images for both purposes will be collected at the same time. The new images from the hands, head\u002Fface, and feet will then be combined with existing images from other body areas. This will allow researchers to determine whether the updated AI system performs as well as, or better than, previous versions of the technology. For participants with Study Burns requiring surgical excision, the Study site clinician will collect punch biopsies from the Study Burn according to a standardised burn wound punch biopsy collection.",[24,25,26],"Burns","Burn Injury","Diagnostic","NOT_YET_RECRUITING","2026-06-24",{"date":30,"type":31},"2026-07-01","ACTUAL",{"date":33,"type":20},"2026-09-01",{"date":35,"type":20},"2027-05-01",{"name":37,"class":38},"SpectralMD","INDUSTRY",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100624160","optical-characterization-and-multi-modality-multi-scale-modeling-of-human-skin-applied-to-cancer-diagnosis-100624160","NCT07406022","Optical Characterization and Multi-modality, Multi-scale Modeling of Human Skin Applied to Cancer Diagnosis.","OpticSkin","Inclusion Criteria:\n\n* patients with skin carcinomas and actinic keratoses\n\nExclusion Criteria:\n\n* minor patient","18 Years",{"count":48,"type":20},140,"Skin carcinomas are the most commonly diagnosed cancers in fair-skinned populations, for example in France, Western Europe, and North America in particular. The OpticSkin project will build and make available to the general public and the scientific and medical community a histological and optical spectroscopic database of healthy, precancerous, and cancerous human skin in terms of absorption, elastic and inelastic scattering (Raman), steady-state and time-resolved autofluorescence, and polarization. The aim is to identify spectroscopic signatures that will be useful for diagnosis.",[51,26],"Skin Cancer","RECRUITING","2026-06-23",{"date":28,"type":31},{"date":56,"type":31},"2025-12-01",{"date":58,"type":20},"2029-12-31",{"name":60,"class":61},"Centre Hospitalier Régional Metz-Thionville","OTHER",1,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":62},"100635625","night-to-night-variability-of-novel-physiological-parameters-in-home-sleep-apnea-testing-100635625","NCT07555119","Night-to-Night Variability of Novel Physiological Parameters in Home Sleep Apnea Testing","N2N-OSA","Inclusion Criteria:\n\n* Patients with suspected or diagnosed sleep-disordered breathing, irrespective of disease severity, as defined by the indications for home sleep apnea testing in the German guidelines \\[15\\]\n* No active treatment during sleep recordings or within preceding two weeks (e.g., mandibular advancement devices, positive airway pressure therapy)\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Known or suspected neurological sleep disorder (e.g., narcolepsy, parasomnia)\n* Known or suspected psychiatric sleep disorder\n* Known or suspected central and complex sleep apnea\n* Participants who are unable to perform sleep measurements reliably\n* Insufficient knowledge of the project language (German)\n* Inability to give consent\n* Shift workers (with shift work \\\u003C2 weeks before testing)",{"count":71,"type":20},192,"Obstructive sleep apnea (OSA) is usually diagnosed from a single night of home sleep apnea testing using the apnea-hypopnea index (AHI). However, the AHI varies substantially from night to night, undermining diagnostic accuracy, and shows only modest correlation with symptoms. This variability further limits its usefulness for predicting cardiovascular and other complications. Besides the traditional AHI, more robust physiological markers are needed.\n\nSeveral emerging physiological metrics - hypoxic burden, ventilatory burden, heart rate variability, autonomic arousals, and the pulse wave amplitude drop index - capture the physiological impact of OSA more comprehensively and demonstrate stronger associations with cardiovascular risk. Despite this promise, their night-to-night variability has not been studied.\n\nA systematic evaluation of both established and novel OSA metrics across nights is essential to identify reliable, stable parameters suitable for clinical routine. This improves diagnostic precision beyond what traditional metrics can provide, enhances patient selection, reduces costs and patient harm, and may improve treatment outcomes.",[74,26,75],"Obstructive Apnea","Sleep Apnea Syndrome (OSAS)",[77],"Home Sleep Apnea Testing","2026-04-28",{"date":80,"type":31},"2026-05-05",{"date":82,"type":20},"2026-05-01",{"date":84,"type":20},"2027-06-30",{"name":86,"class":61},"Insel Gruppe AG, University Hospital Bern",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":95,"sex":17,"minAge":46,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":99,"conditions":100,"keywords":104,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":114,"leadSponsor":116,"locationsCount":4},"100612473","ai-assisted-saliva-diagnostics-using-an-electrochemical-sensor-platform-for-periodontitis-detection-salience-100612473","NCT07254039","AI-Assisted Saliva Diagnostics Using an Electrochemical Sensor Platform for Periodontitis Detection (SALIENCE)","Development and Validation of an AI-Assisted Electrochemical Sensor Platform for Saliva-Based Diagnostics in Periodontitis","SALIENCE","Inclusion Criteria:\n\nAdults ≥18 years.\n\nAble and willing to provide written informed consent.\n\nAbility to provide an unstimulated whole saliva sample per protocol (no food, drink, gum, toothbrushing, or smoking within 60 minutes prior to sampling).\n\nPeriodontitis group: Clinical diagnosis of periodontitis according to 2018 AAP\u002FEFP criteria (e.g., interdental CAL ≥3 mm at ≥2 non-adjacent teeth with radiographic bone loss; probing pocket depth ≥4 mm in ≥2 teeth).\n\nHealthy control group: No clinical signs of periodontal disease (no probing depths \\>3 mm, bleeding on probing \\\u003C10%, and no radiographic bone loss).\n\nExclusion Criteria:\n\nSystemic antibiotics or systemic anti-inflammatory\u002Fimmunosuppressive therapy within the past 3 months.\n\nPeriodontal therapy (scaling\u002Froot planing or surgery) within the past 6 months.\n\nCurrent acute oral infection or abscess.\n\nSystemic conditions known to markedly alter saliva composition\u002Fflow (e.g., Sjögren's syndrome, prior head-and-neck radiation, ongoing chemotherapy, uncontrolled diabetes).\n\nUse of strongly xerogenic medications not on a stable dose ≥4 weeks, or clinically significant hyposalivation preventing sampling.\n\nInability to comply with sampling procedures (e.g., cannot abstain from food\u002Fdrink\u002Ftobacco for 60 minutes prior to sampling).\n\nPregnancy or lactation.",true,"80 Years",{"count":98,"type":20},200,"This observational study aims to develop and validate a novel, AI-assisted electrochemical sensor platform for saliva-based diagnostics in periodontitis. Periodontitis is a chronic inflammatory disease affecting the gums and supporting tissues of the teeth. Despite its high global prevalence, early diagnosis remains challenging because the disease often progresses silently until irreversible damage has occurred.\n\nSaliva offers a promising, non-invasive diagnostic medium that reflects both oral and systemic health. However, its biological complexity and variability have limited its clinical use. This project addresses these challenges by combining advanced electrochemical sensing with artificial intelligence (AI) and synthetic data generation to improve diagnostic precision and reliability.\n\nThe study involves the collection of saliva samples from adult participants with diagnosed periodontitis and from healthy controls. The samples will be analyzed using a modular sensor platform equipped with multiple electrodes that detect electrochemical signals from a wide range of salivary biomarkers. The sensor data will then be processed using machine learning models trained on both real and synthetic data to classify disease states.\n\nThe main goals are to:\n\nEvaluate the performance of the electrochemical sensor array for saliva analysis.\n\nDevelop and validate AI-based algorithms for detecting and differentiating between healthy and diseased samples.\n\nGenerate feasibility data supporting future clinical implementation of saliva-based diagnostics for periodontitis.\n\nThis interdisciplinary project combines expertise in clinical dentistry, biomedical engineering, and computer science. It is conducted in collaboration between Linköping University and Malmö University, with patient sampling carried out at an affiliated dental clinic.\n\nThe study is expected to result in a working proof-of-concept device that enables real-time, non-invasive detection of periodontitis at the point of care. By enabling earlier diagnosis and more personalized treatment, this technology may transform periodontal care and serve as a foundation for future saliva-based diagnostics targeting other oral and systemic diseases.",[101,102,26,103],"Periodontal Diseases","Biomarkers (D23.050.301)","Saliva",[105,106,107,108,109],"Saliva Diagnostics","Electrochemical Sensor","AI-Assisted Diagnostics","Biomarkers","Periodontal diseases","2025-11-19",{"date":112,"type":31},"2025-11-28",{"date":56,"type":20},{"date":115,"type":20},"2028-06-30",{"name":117,"class":61},"Ostergotland County Council, Sweden",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":125,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":130,"phases":131,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":146,"leadSponsor":148,"locationsCount":4},"100579764","female-genital-schistosomiasis-in-migrant-women-a-pilot-study-100579764","NCT06828536","Female Genital Schistosomiasis in Migrant Women: A Pilot Study","GynoBizh","Inclusion Criteria:\n\n* Women aged 25 to 65 years\n* Born in a schistosomiasis-endemic area in sub-Saharan Africa\n* With a positive serology by Schistosoma spp. Western Blot\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* Patient unable to provide consent\n* Patient under guardianship or trusteeship\n* Patient who is a virgin at the time of selection\n* Patient who is pregnant at the time of selection","FEMALE","25 Years","65 Years",{"count":129,"type":20},50,"INTERVENTIONAL",[132],"NA","This pilot study, \"GynoBizh,\" investigates the frequency and clinical characteristics of female genital schistosomiasis (FGS) among migrant women from sub-Saharan Africa living in non-endemic countries. Schistosomiasis is a significant global parasitic disease, with a high seroprevalence in migrants. The study aims to assess the presence of genital lesions through gynecological examinations, colposcopy, and molecular tests, identifying diagnostic markers and associated health conditions. Fifty participants will be followed over a year to improve understanding and management of FGS in underserved populations.",[26,135],"Schistosomiasis",[137,138,139,140,141],"femal genital schistosomiasis","migrant women","colposcopy","Diagnostic pilot study","Schistosoma spp. PCR","2025-02-10",{"date":144,"type":31},"2025-02-14",{"date":142,"type":20},{"date":147,"type":20},"2026-08-10",{"name":149,"class":61},"Assistance Publique - Hôpitaux de Paris",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":156,"targetDuration":158,"studyType":21,"phases":4,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":62},"100534031","a-study-on-diagnosis-and-treatment-strategies-for-atlantoaxial-dislocation-100534031","NCT06233539","A Study on Diagnosis and Treatment Strategies for Atlantoaxial Dislocation","Inclusion Criteria:\n\n* Patients diagnosed with atlantoaxial dislocation and treated with surgery\n\nExclusion Criteria:\n\n* Disagree to participate in this study.",{"count":157,"type":20},3000,"1 Year","The most effective treatment for atlantoaxial dislocation is surgical treatment, with the principle of achieving reduction, reconstruction, and fusion of the atlantoaxial joint. The surgical strategies mainly include simple anterior approach, simple posterior approach, and combined anterior posterior approach. The investigators have summarized 904 cases of atlantoaxial instability or dislocation from 1998 to 2010 and preliminarily published the diagnosis and treatment strategy tree of the Third Hospital of Beijing Medical University. This strategy is divided into four types based on the severity of atlantoaxial dislocation: unstable, reversible, difficult to recover, and skeletal, and enters different surgical treatment processes. With the increase in the number of cases, accumulation of experience, and technological improvements in the past decade, spinal surgery colleagues have updated their classification diagnosis, diagnosis and treatment processes, and surgical techniques for atlantoaxial instability or dislocation.\n\nHowever, the selection of treatment strategies for atlantoaxial dislocation is mostly based on the surgeon's own experience, and there is a lack of standardized, large-scale, and high-level evidence-based medical research on the safety and effectiveness of current empirical strategies. Based on this, this study intends to adopt a multicenter, retrospective, and prospective study to construct a high-quality clinical cohort of atlantoaxial dislocation, update the classification and diagnosis and treatment strategies of atlantoaxial dislocation. And conduct long-term follow-up on patients to evaluate their safety and effectiveness, guide the surgical treatment of atlantoaxial dislocation, and thus form a recognized diagnostic and treatment standard for atlantoaxial dislocation.",[161,162,26],"Atlantoaxial Dislocation","Treatment","2024-04-01",{"date":165,"type":31},"2024-04-03",{"date":167,"type":31},"2022-12-01",{"date":169,"type":20},"2026-12-31",{"name":171,"class":61},"Peking University Third Hospital"]